Details of the Drug Combination

General Information of Drug Combination (ID: DCTBUB2)

Drug Combination Name

Picoplatin TEM

Indication

Disease Entry	Status	REF
Minimally invasive lung adenocarcinoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

TEM DMLNFWU

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: NCI-H322M

Zero Interaction Potency (ZIP) Score: 3.67

Bliss Independence Score: 11.46

Loewe Additivity Score: 6.6

LHighest Single Agent (HSA) Score: 9.36

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DC0898C	DU-145	Investigative	[1]
Adenocarcinoma	DCVY6C4	HCT116	Investigative	[1]
Large cell lung carcinoma	DCG8LNV	NCI-H460	Investigative	[1]
Prostate carcinoma	DCN37EB	PC-3	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)